CANSINOBIO (06185.HK) has completed the enrollment of the first subject in the Phase II clinical trial of the Tdcp vaccine.

CANSINOBIO (06185.HK) announced that the clinical trial phase II/III for its adsorbed acellular diphtheria, tetanus, and pertussis combined vaccine (Tdcp vaccine for adolescents and adults) has officially started recently, and the first subject has been recruited for the phase II clinical trial.

AASTOCKSDec 22 20:19

CanSino Biologics Inc. (688185.SH): Some controlling shareholders collectively used approximately 5.6705 million Hong Kong dollars to increase their Shareholding by 0.278 million shares Listed in Hong Kong.

Gelonghui reported on December 20 that CanSino Biologics Inc. (688185.SH) announced that it has received a notice regarding the completion of the shareholding plan from certain controlling shareholders, XUEFENGYU (Yu Xuefeng), Zhu Tao, SHOU BAICHAO (Chao Shoubo), and Executive Director and Senior Management, Wang Jing. During the implementation of this shareholding plan, XUEFENGYU (Yu Xuefeng), Zhu Tao, and SHOU BAICHAO (Chao Shoubo) increased their holdings by 100,000 shares, 110,000 shares, respectively, based on their assessment of the securities market, funding arrangements for the increase, and the increase window period.

Gelonghui FinanceDec 20 17:35

Express News | CanSino Biologics Inc.: Phase II/III clinical trial for Tdcp in adolescents and adults has been initiated, and the first participant in Phase II clinical trial has been enrolled.

BreakingsDec 20 17:32

Express News | CanSino Biologics Inc.: The Phase I/II clinical trial of the recombinant poliovirus vaccine has been launched and the first participant has been enrolled.

BreakingsDec 20 17:29

Express News | The USA Biological Security Act was not included in the CR bill.

BreakingsDec 18 15:53

Express News | Some Hong Kong pharmaceutical stocks are rising, with Lepu Biotech up nearly 6%.

BreakingsDec 17 09:43